Trends in biologic therapies for rheumatoid arthritis: Results from a survey of payers and providers

American Health and Drug Benefits

Volumn 5, Issue 2, 2012, Pages 83-92

  Greenapple, Rhonda ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; MEDICAL DOCUMENTATION; OUTCOME ASSESSMENT; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT PLANNING; TREND STUDY;

EID: 84863650051     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72:1037-1047.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-911.
3. Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62:1576-1582.
4. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5 suppl 31):S71-S74.
5. Verstappen SM, Bijlsma JW, Verkleij H, et al; Utrecht Rheumatoid Arthritis Cohort Study Group. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum. 2004;51:488-497.
6. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-1588.
7. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.
8. Allaire S, Wolfe F, Niu J, LaValley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008;59:474-480.
9. Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care. 2010;16(9 suppl):S249-S258.
10. Cush JJ. American College of Rheumatology. Biologic treatments for rheumatoid arthritis. 2010. www.rheumatology.org/practice/clinical/patients/medications/biologics.pd f. Accessed January 26, 2012.
11. Effective Health Care, Agency for Healthcare Research and Quality. Rheumatoid arthritis medicines: a guide for adults. AHRQ Publication Number 08-EHC004-2A; April 2008. www.effectivehealthcare.ahrq.gov/repFiles/RheumArthritisConsumerGuide_Si nglepage.pdf. Accessed March 1, 2012.
12. Hoadley J, Henry J. Kaiser Foundation. Cost containment strategies for prescription drugs: assessing the evidence in the literature. March 2005. www.kff.org/rxdrugs/upload/Cost-Containment-Strategies-for-Precription-D rugs-Assessing-The-Evidence-in-the-Literature-Report.pdf. Accessed March 1, 2012.
13. Rigel Pharmaceuticals, Inc. Rigel's R788 significantly improves rheumatoid arthritis in phase 2b clinical trial: expected and manageable safety profile demonstrated in TASKi2. Media release. July 9, 2009. www.drugs.com/clinical_trials/rigels-r788-significantly-improves-rheumat oid-arthritis-phase-2b-clinical-trial-7714.html. Accessed March 2, 2012.
14. van Vollenhoven RF, Fleischmann RM, Cohen SB, et al. Tofacitinib (CP- 690,550), an oral Janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a phase 3 study. Arthritis Rheum. 2011;63(suppl 10):408.
15. EMD Serono. Managed care strategies for management of specialty injectable drugs. EMD Serono Injectables Digest. 4th ed. 2008. www.amcp.org/WorkArea/DownloadAsset.aspx?id=12974. Accessed January 26, 2012.
16. Medco. 2011 Drug Trend Report: Healthcare 2020. Franklin Lakes, NJ: Medco; 2011. www.drugtrendreport.com/Medco-2011-Drug-Trend-Report-Executive-Summary.p df. Accessed March 1, 2012.